Optimization of RAASi and low risk of hyperkalemia with potassium binder in HFrEF

Media formats available:

No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
ACC.24
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
- Javed Butler, MD
Clinical implications of the evidence from IV iron trials in HF
Clinical implications of the evidence from IV iron trials in HF
Heart Failure
Clinical implications of the evidence from IV iron trials in HF
- Stefan D. Anker, MD, PhD
- Robert J. Mentz, MD, FHFSA, FACC, FAHA
- Piotr Ponikowski, MD, PhD, FESC, FHFA
2023 ESC Guideline Updates: Where are we with iron deficiency?
2023 ESC Guideline Updates: Where are we with iron deficiency?
Heart Failure
2023 ESC Guideline Updates: Where are we with iron deficiency?
- Giuseppe M.C. Rosano, MD, PhD
- Marco Metra, MD
- Gianluigi Savarese, MD
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
Kidney Disease
A multidisciplinary approach to managing potassium levels in patients with HF when optimizing RAASi therapy
- Antoni Bayés-Genís, MD, PhD
- Patrick Rossignol, MD, PhD

PACE-CME